Montreal, QC --
December 13, 2018 -- InvestorsHub
NewsWire -- Relevium
Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt:
“6BX”) (the
“Company” or “Relevium”),
is pleased to announce that it has launched its Leefylyfe™ brand of organically
sourced full spectrum hemp CBD products on a pre-order basis in the
UK.
The Company is launching
three initial organically sourced, whole plant Hemp CBD rich oils
in product and tincture formats that maintain a full spectrum of
secondary cannabinoids, terpene profiles and flavonoids for
wellbeing. The company plans to launch several exclusive
formulations of its Leefylyfe™ branded products in 2019 and plans
to extend sales to the rest of Europe.
Pending the confirmation of
the Farm Bill, which was recently approved by the US Senate, the
Company plans to conduct a full launch if its new brand in the US,
which is expected to be powered by its trusted Bioganix® brand of
nutraceutical and skin care products.
“The entire Relevium
team is proud and excited to launch LeefyLyfe™ on a pre-order
basis. Our product strategy is to source locally in Europe, from
GMP and Certified Organic producers, a Hemp product that is natural
and rich in cannabinoids while respecting the THC threshold that is
legally acceptable in the region”. Sated Aurelio
Useche, CEO.
“The launch of
LeefyLyfe™ is consistent with our focus on
creating new revenue streams, diversifying
the product offering and continuing to elevate our trusted brands.
The company is actively integrating Phyto-cannabinoids into its OTC
business to provide bring the natural goodness of Hemp to its
portfolio and trusted Health and Wellness
products” stated Abis Hussain, Chief Marketing
Officer.
About Relevium
Technologies
Relevium is a
publicly-traded company that operates in the health and wellness
industry, including legal cannabis, with a primary focus on online
distribution. The principal business of the Company is the
identification, evaluation, acquisition and operations of brands
and businesses in the Health and Wellness markets and medical
cannabis. The Company pursues its business strategy through an
acquisition and partnership model in a holistic approach to
encompass a wide range of health and wellness consumer
products.
Relevium operates through
two wholly-owned subsidiaries:
BGX E-Health LLC
(BGX): Based in Orlando, Florida, BGX markets dietary
supplements, nutraceuticals, sports nutrition and cosmeceuticals
primarily through its Bioganix® brand portfolio in the US and
Europe. Relevium’s brands such as Bioganix® are
sold at some of the world’s largest retailers including such as
Walmart.com and Amazon.com.
The Company’s strategy for
growing its brands includes expanding its product offering, adding
new distribution channels and developing partnerships that add
value through exclusive ingredients. BGX is currently testing a
complete line of dietary supplements derived from Cannabis with an
initial focus on hemp derived, whole plant organic extract rich in
CBD (cannabidiol). The product line will be marketed through its
brand LeefyLyfe® and will be sold first in Europe and then North
America. The Company uses cannabinoids and ingredients that have
achieved GRAS status (generally accepted as safe) to create brands
that are sold via wholesale channels, retail channels and online
distribution.
Biocannabix Health
Corporation (BCX): Based in Montreal, Quebec, BCX is
an entrepreneurial venture to establish a vertically integrated
medical cannabis company in the Nutraceutical space. Located in the
city of Saint Laurent, the Company is in the process of licensing
and retrofitting a facility that will host a genetically focused
cannabis growth, extraction, formulation, research and development
and encapsulation of proprietary Nutraceutical and Medical
products.
Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Cautionary Note
Regarding Forward-Looking Statements
This release includes
certain statements and information that may constitute
forward-looking information within the meaning of applicable
Canadian securities laws. All statements in this news release,
other than statements of historical facts, including statements
regarding future estimates, plans, objectives, assumptions or
expectations of future performance, including the timing and
completion of the proposed acquisitions, are forward-looking
statements and contain forward-looking information. Generally,
forward- looking statements and information can be identified by
the use of forward-looking terminology such as "intends" or
"anticipates", or variations of such words and phrases or
statements that certain actions, events or results "may", "could",
"should", "would" or "occur". Forward-looking statements are based
on certain material assumptions and analysis made by the Company
and the opinions and estimates of management as of the date of this
press release, including the assumptions that the Company will be
able to apply for and ultimately obtain an ACMPR license, the
proposed business of Biocannabix will develop as anticipated, that
the Company will raise sufficient funds to develop the Biocannabix
business, and that the Company will obtain all requisite regulatory
approvals. These forward-looking statements are subject to known
and unknown risks, uncertainties and other factors that may cause
the actual results, level of activity, performance or achievements
of the Company to be materially different from those expressed or
implied by such forward-looking statements or forward-looking
information. Important factors that may cause actual results to
vary, include, without limitation, the risk that the proposed
business developments may not occur as planned; the timing and
receipt of requisite approvals and failure to raise enough
funds.
Although management of the
Company has attempted to identify important factors that could
cause actual results to differ materially from those contained in
forward-looking statements or forward-looking information, there
may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward- looking statements and forward-looking information.
Readers are cautioned that reliance on such information may not be
appropriate for other purposes. The Company does not undertake to
update any forward-looking statement, forward-looking information
or financial outlook that are incorporated by reference herein,
except in accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of
Directors
RELEVIUM
TECHNOLOGIES INC.
Aurelio
Useche
President and CEO
For more information about
this press release:
RELEVIUM
TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow
us on LinkedIn